[go: up one dir, main page]

IL143221A0 - Combination of cerivastatin and fibrates - Google Patents

Combination of cerivastatin and fibrates

Info

Publication number
IL143221A0
IL143221A0 IL14322199A IL14322199A IL143221A0 IL 143221 A0 IL143221 A0 IL 143221A0 IL 14322199 A IL14322199 A IL 14322199A IL 14322199 A IL14322199 A IL 14322199A IL 143221 A0 IL143221 A0 IL 143221A0
Authority
IL
Israel
Prior art keywords
fibrates
cerivastatin
combination
Prior art date
Application number
IL14322199A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL143221A0 publication Critical patent/IL143221A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
IL14322199A 1998-12-18 1999-12-06 Combination of cerivastatin and fibrates IL143221A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19858789A DE19858789A1 (de) 1998-12-18 1998-12-18 Kombination von Cerivastatin und Fibraten
PCT/EP1999/009524 WO2000037078A1 (de) 1998-12-18 1999-12-06 Kombination von cerivastatin und fibraten

Publications (1)

Publication Number Publication Date
IL143221A0 true IL143221A0 (en) 2002-04-21

Family

ID=7891784

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14322199A IL143221A0 (en) 1998-12-18 1999-12-06 Combination of cerivastatin and fibrates

Country Status (19)

Country Link
US (1) US6511985B1 (es)
EP (1) EP1140082A1 (es)
KR (1) KR20010093845A (es)
CN (1) CN1330544A (es)
AR (1) AR021643A1 (es)
AU (1) AU3035600A (es)
BR (1) BR9916270A (es)
CA (1) CA2355295A1 (es)
CO (1) CO5160272A1 (es)
DE (1) DE19858789A1 (es)
GT (1) GT199900214A (es)
HN (1) HN1999000208A (es)
IL (1) IL143221A0 (es)
PE (1) PE20001325A1 (es)
PL (1) PL349389A1 (es)
SV (1) SV1999000250A (es)
TR (1) TR200101722T2 (es)
WO (1) WO2000037078A1 (es)
ZA (1) ZA200103918B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1322289B1 (en) 2000-09-20 2007-07-25 Jagotec AG Spray drying process of compositions containing fenofibrate
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1355644T1 (sl) 2001-01-26 2006-10-31 Schering Corp Uporaba substituiranih azetidinonskih spojin za zdravljenje sitosterolemije
EP1361867B1 (en) * 2001-02-22 2007-03-21 Jagotec AG Fibrate-statin combinations with reduced fed-fasted effects
EP1414496B1 (en) 2001-08-07 2010-10-20 Galephar M/F Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride
WO2003013607A1 (en) * 2001-08-07 2003-02-20 Galephar M/F ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DK1429756T3 (da) 2001-09-21 2007-03-19 Schering Corp Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1812983A (zh) * 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
JP4839221B2 (ja) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Ｈｄｌを高める併用療法用複合物
MX2007009281A (es) * 2005-02-10 2007-09-25 Lufecycle Pharma As Composicion farmaceutica estable que comprende una combinacion de dosis fija de fenofibrato y un inhibidor de 3-hidroxi 3-metilglutaril-coenzima a reductasa.
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
CL2007002044A1 (es) * 2006-07-14 2008-06-13 Ranbaxy Lab Ltd Polimorfo cristalino de la sal hemicalcica del acido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxiheptanoico; composicion farmaceutica; y uso para el tratamiento de la diabetes, enf
CA2657394A1 (en) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
WO2023146320A1 (ko) * 2022-01-28 2023-08-03 동광제약 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염 및 페노피브레이트를 함유하는 캡슐 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494112B1 (es) 1980-11-19 1986-01-10 Laruelle Claude
EP0276807A3 (en) 1987-01-27 1988-10-12 Warner-Lambert Company Lipid regulating compositions
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
CA2039763A1 (en) * 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
DK1017390T3 (da) * 1997-07-31 2007-06-11 Kos Life Sciences Inc Coated tablet, der omfatter nikotinsyre eller en forbindelse, der metaboliseres til nikotinsyre, i en form med langvarig frigivelse og en HMG-CoA-reduktaseinhibitor i en form med öjeblikkelig frigivelse

Also Published As

Publication number Publication date
HN1999000208A (es) 2000-11-22
CO5160272A1 (es) 2002-05-30
WO2000037078A1 (de) 2000-06-29
SV1999000250A (es) 2000-10-16
ZA200103918B (en) 2002-05-15
CA2355295A1 (en) 2000-06-29
DE19858789A1 (de) 2000-06-21
PL349389A1 (en) 2002-07-15
GT199900214A (es) 2001-06-08
TR200101722T2 (tr) 2001-11-21
BR9916270A (pt) 2001-09-04
US6511985B1 (en) 2003-01-28
EP1140082A1 (de) 2001-10-10
PE20001325A1 (es) 2000-12-30
AU3035600A (en) 2000-07-12
KR20010093845A (ko) 2001-10-29
AR021643A1 (es) 2002-07-31
CN1330544A (zh) 2002-01-09

Similar Documents

Publication Publication Date Title
IL143221A0 (en) Combination of cerivastatin and fibrates
IL183948A0 (en) Conjugates of peg-urate oxidase and use thereof
HU9900592D0 (en) Compound and its use
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
PL347357A1 (en) Novel composition and use
GB9813271D0 (en) Composition and use
PL333764A1 (en) Lamp and way of its operation
ZA985096B (en) Composition compound and use
PL347689A1 (en) Absorbent product with arcuate longsides of end portion
PL343430A1 (en) Preparation and purification of diborane
EP1056455A4 (en) EPIMORPHIN COMPOUND AND USE OF THE SAME
GB9803232D0 (en) Compound composition and use
HUP0103309A3 (en) Novel salts of n-tert-butylhydroxylamine and preparation thereof
GB9807586D0 (en) Enzymes and their use
GB0118888D0 (en) Peak and/or trough detectors
GB9918174D0 (en) Disc covers and methods of manufacture thereof
GB9805172D0 (en) Composition and use
GB9802016D0 (en) Bootsac and coolsac
TW354479U (en) Improvement of earpick
GB9824869D0 (en) Novel composition and use
GB9824866D0 (en) Novel composition and use
GB9824870D0 (en) Novel composition and use
GB9824867D0 (en) Novel composition and use
GB9812758D0 (en) Proteasomal destruction of mRNA
AUPP631998A0 (en) Pillow and anchorage